Table 1.

Baseline Characteristics

	Neratinib +/− Paclitaxel n=115	Paclitaxel +/− trastuzumab n=78
Median Age range	51 (24 – 70)	48 (24–71)
Ethnicity, n (%)
White	92 (80%)	62 (79.5%)
Asian	16 (14%)	11 (14.1%)
African/American	7 (6%)	5 (6.4%)
Menopausal status (%)
Premenopausal	56 (49%)	40 (51%)
Perimenopausal-	4 (3%)	6 (8%)
Postmenopausal	44 (38%)	22 (28%)
Not Applicable	11 (10%)	10 (13%)
HR Status (%)
Positive	60 (52%)	43 (55%)
Negative	55 (48%)	35 (45%)
HER2 Status (%)
Positive (IHC and/or FISH)	65 (57%)	22 (28%)
Negative	50 (43%)	56 (72%)
Clinical presentation
MRI tumor diameter (median, cm)	3.7 (1.5 – 11.8)	3.95 (1.2 – 13)
Axillary node palpable (%)	54 (47%)	36 (46%)
Axillary node non-palpable (%)	61 (53%)	42 (54%)